Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.35%
#2 Pons Pons +32.99%
#3 TENDIES TENDIES +31.51%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.92%
#5 Starpower Starpower +28.46%
#6 StonkBroker StonkBroker +23.95%
#7 Mubarak Mubarak +22.28%
#8 SkyAI SkyAI +22.11%
#9 PondCoin PondCoin +21.09%
#10 Ocean Protocol Ocean Protocol +19.89%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Kedudukan dalam Saham #28997
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Harga Saham
$0.04406501
Disegerakkan terakhir: 2024-07-09
Modal Pasaran
$23.47M
Perubahan (1 hari)
-0.48%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan InDex Pharmaceuticals Holding AB (publ) (INDEX)

Kategori

Healthcare
Pendapatan untuk InDex Pharmaceuticals Holding AB (publ) (INDEX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini InDex Pharmaceuticals Holding AB (publ), pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi InDex Pharmaceuticals Holding AB (publ) dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH